BrainChip (ASX:BRN) plans to investigate redomiciling from Australia to the US to pursue a listing on a US-based securities exchange, according to a Friday filing with the Australian bourse.
If formally pursued, a scheme of arrangement between the company and its shareholders will be proposed, subject to shareholder and Australian court approval. This timing would position the company for redomiciling by late this year or early 2026, the filing said.
The company would seek to delist its securities from the Australian Securities Exchange as part of the process and maintain existing shareholders' securities listed on the US exchange, equivalent in value to their ASX-listed stock, per the filing.
Shares were down 22% in morning trade Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。